BIOMAT Database Logo BIOMAT Database Logo

Severe combined immune deficiency due to a homozygous 3.2-kb deletion spanning the promoter and first exon of the adenosine deaminase gene. 1987

T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Department of Human Genetics, Sylvius Laboratories, University of Leiden, The Netherlands.

We have investigated the structural gene for adenosine deaminase (ADA) in a female infant with ADA deficiency associated severe combined immune deficiency (ADA-SCID) disease and her family by DNA restriction-fragment-length analysis. In this family a new ADA-specific restriction-fragment-length variant was detected, which involves a 3.2-kb deletion spanning the ADA promoter as well as the first exon. It was found that the patient, who was born to a consanguineous couple, was homozygous and both her parents and her brother were heterozygous for the deletion. No ADA-specific mRNA could be detected by hybridization in fibroblasts derived from this patient. Thus the patient was established to be homozygous for a true null ADA allele. In the light of the apparently normal development of most tissues except the lymphoid tissue the above finding directly questions the classification of ADA as a 'housekeeping' enzyme.

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D007223 Infant A child between 1 and 23 months of age. Infants
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D008297 Male Males
D009700 Nucleoside Deaminases Catalyze the hydrolysis of nucleosides with the elimination of ammonia. Deaminases, Nucleoside
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons

Related Publications

T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Adenosine deaminase (ADA) deficiency due to deletion of the ADA gene promoter and first exon by homologous recombination between two Alu elements.
May 1988, The Journal of clinical investigation,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Severe combined immunodeficiency due to adenosine deaminase deficiency.
March 2012, JPMA. The Journal of the Pakistan Medical Association,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
February 2012, Current gene therapy,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.
December 2009, Stem cells and cloning : advances and applications,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Severe Growth Hormone Deficiency in an Indian Boy Caused By a Novel 6 kb Homozygous Deletion Spanning the GH1 Gene.
February 2023, Journal of clinical research in pediatric endocrinology,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Gene therapy techniques in the treatment of adenosine deaminase--deficiency severe combined immune deficiency syndrome.
March 1994, The Journal of perinatal & neonatal nursing,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Severe phenotype of severe combined immunodeficiency caused by adenosine deaminase deficiency in a patient with a homozygous mutation due to uniparental disomy.
July 2013, The Journal of allergy and clinical immunology,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
October 2021, Blood,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Severe combined immune deficiency in an adenosine deaminase-deficient patient.
January 2006, Allergy and asthma proceedings,
T M Berkvens, and E J Gerritsen, and M Oldenburg, and C Breukel, and J T Wijnen, and H van Ormondt, and J M Vossen, and A J van der Eb, and P Meera Khan
Severe combined immunodeficiency disease, adenosine deaminase deficiency and gene therapy.
August 1991, Current opinion in immunology,
Copied contents to your clipboard!